Lytix Biopharma has agreed with Institut Gustave Roussy, Paris, to enter into a new collaboration period with professor Laurence Zitvogel, a leading expert on the interaction between the immune system and cancer. Zitvogel`s group has documented a strong synergy between anti-CTLA4 and LTX-315 and will continue to investigate the immunological signature of LTX-315 alone, and combinations with different checkpoint blockade inhibitors.

Lytix Biopharma is also collaborating with professor Guido Kroemer at IGR, one of the world’s leading experts in mechanisms of cancer cell death. Kroemer`s group is investigating the cytocidal mode of action of LTX-315.